新型冠状病毒病患者的肺栓塞与 d-二聚体水平升高。
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
出版信息
Emerg Infect Dis. 2020 Aug;26(8):1941-1943. doi: 10.3201/eid2608.201477. Epub 2020 Apr 29.
Abstract
We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.
摘要
我们报告了 3 例在住院期间呼吸状况恶化的新型冠状病毒病患者，他们对静脉注射类固醇和白细胞介素-6 受体拮抗剂治疗反应良好。这些患者后来出现持续性低氧血症，D-二聚体水平升高，并被诊断为肺栓塞。
相似文献
1
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.新型冠状病毒病患者的肺栓塞与 d-二聚体水平升高。
Emerg Infect Dis. 2020 Aug;26(8):1941-1943. doi: 10.3201/eid2608.201477. Epub 2020 Apr 29.
2
COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.COVID-19 与产后患者的急性肺栓塞。
Emerg Infect Dis. 2020 Aug;26(8):1937-1939. doi: 10.3201/eid2608.201383. Epub 2020 May 12.
3
Thromboembolic events and Covid-19.血栓栓塞事件与新型冠状病毒肺炎
Adv Biol Regul. 2020 Aug;77:100735. doi: 10.1016/j.jbior.2020.100735. Epub 2020 Jun 17.
4
Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.感染新型冠状病毒（SARS-CoV-2）患者的血栓栓塞事件及明显的肝素抵抗
Int J Lab Hematol. 2020 Jun;42 Suppl 1(Suppl 1):19-20. doi: 10.1111/ijlh.13230.
5
Coagulopathy in COVID-19: Focus on vascular thrombotic events.新型冠状病毒肺炎相关凝血功能障碍：关注血管血栓栓塞事件。
J Mol Cell Cardiol. 2020 Sep;146:32-40. doi: 10.1016/j.yjmcc.2020.07.003. Epub 2020 Jul 15.
6
COVID-19 and Hypercoagulability.新型冠状病毒肺炎与高凝状态
Clin Adv Hematol Oncol. 2020 Jul;18(7):386-389.
7
IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.IP-10 和 MCP-1 作为与 COVID-19 疾病严重程度相关的生物标志物。
Mol Med. 2020 Oct 29;26(1):97. doi: 10.1186/s10020-020-00230-x.
8
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).COVID-19 相关急性呼吸窘迫综合征患者接受托珠单抗治疗的死亡率预测因素。
Microbes Infect. 2020 Oct;22(9):500-503. doi: 10.1016/j.micinf.2020.06.005. Epub 2020 Jun 20.
9
Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?COVID-19 相关静脉血栓栓塞症：目前我们了解多少？
Acta Haematol. 2020;143(5):417-424. doi: 10.1159/000508233. Epub 2020 May 12.
10
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.静脉注射N-乙酰半胱氨酸对重症新型冠状病毒肺炎感染进行炎症的治疗性阻断。
Clin Immunol. 2020 Oct;219:108544. doi: 10.1016/j.clim.2020.108544. Epub 2020 Jul 22.
引用本文的文献
1
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.新冠后遗症（PASC 或长期新冠）：基于证据的方法。
Open Forum Infect Dis. 2024 Aug 27;11(9):ofae462. doi: 10.1093/ofid/ofae462. eCollection 2024 Sep.
2
Vascular dysfunction in hemorrhagic viral fevers: opportunities for organotypic modeling.出血性病毒性发热中的血管功能障碍：器官型建模的机会。
Biofabrication. 2024 Jun 5;16(3):032008. doi: 10.1088/1758-5090/ad4c0b.
3
Novel inflammatory markers in patients with severe COVID-19 and a pulmonary thrombotic event.患有重症新型冠状病毒肺炎（COVID-19）并发生肺血栓形成事件患者的新型炎症标志物。
Cent Eur J Immunol. 2023;48(3):167-173. doi: 10.5114/ceji.2023.131382. Epub 2023 Sep 21.
4
Development of a new prognostic index PNPI for prognosis prediction of CKD patients with pneumonia at hospital admission.开发一种新的预后指数PNPI，用于预测入院时患有肺炎的慢性肾脏病患者的预后。
Front Med (Lausanne). 2023 Aug 10;10:1135586. doi: 10.3389/fmed.2023.1135586. eCollection 2023.
5
Pulmonary Embolism and Giant Cavitary Lesion Developing After COVID-19 Pneumonia.新冠病毒肺炎后发生的肺栓塞和巨大空洞性病变
HCA Healthc J Med. 2020 Nov 28;1:365-368. doi: 10.36518/2689-0216.1109. eCollection 2020.
6
Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis.直接口服抗凝剂与肝素预防 COVID-19 住院患者血栓栓塞的疗效和安全性比较：系统评价和荟萃分析。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231164355. doi: 10.1177/10760296231164355.
7
Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).SARS-CoV-2 感染后后遗症（PASC）的发病机制。
Elife. 2023 Mar 22;12:e86002. doi: 10.7554/eLife.86002.
8
Artificial intelligence and discrete-event simulation for capacity management of intensive care units during the Covid-19 pandemic: A case study.人工智能与离散事件模拟在新冠疫情期间重症监护病房容量管理中的应用：一项案例研究
J Bus Res. 2023 May;160:113806. doi: 10.1016/j.jbusres.2023.113806. Epub 2023 Mar 3.
9
The analysis of Fe-dependent serum enzymes in severe COVID-19 with a pulmonary thrombotic event.伴有肺血栓形成事件的重症新型冠状病毒肺炎中与铁相关的血清酶分析。
Cent Eur J Immunol. 2022;47(4):293-298. doi: 10.5114/ceji.2022.124076. Epub 2023 Jan 13.
10
Large-scale application of named entity recognition to biomedicine and epidemiology.命名实体识别在生物医学与流行病学中的大规模应用。
PLOS Digit Health. 2022 Dec 7;1(12):e0000152. doi: 10.1371/journal.pdig.0000152. eCollection 2022 Dec.
本文引用的文献
1
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic.COVID-19大流行期间肺栓塞的诊断评估
J Nucl Med. 2020 May;61(5):630-631. doi: 10.2967/jnumed.120.245571. Epub 2020 Apr 1.
2
Acute pulmonary embolism and COVID-19 pneumonia: a random association?急性肺栓塞与新型冠状病毒肺炎：一种随机关联？
Eur Heart J. 2020 May 14;41(19):1858. doi: 10.1093/eurheartj/ehaa254.
3
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Zotero 插件